CompletedPhase 2

Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery

United States103 participantsStarted 2012-12

Plain-language summary

The study will compare how well PF-06473871 works versus placebo in reducing skin scarring after scar revision surgery of existing breast scars. The study will also evaluate the safety of PF-06473871 in healthy adult subjects.

Who can participate

Age range18 Years – 55 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Subjects must have hypertrophic (raised) breast scars from previous surgery * Subjects must be healthy Exclusion Criteria: * Currently pregnant or pregnant during the 6 months, prior to inclusion in the study or breast-feeding. * Presence of history of breast cancer

What they're measuring

Physician Global Assessment Using Physician Overall Opinion Question of Patient and Observer Scar Assessment Scale (POSAS)

Timeframe: Week 24

Trial details

NCT IDNCT01730339

SponsorPfizer

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2014-10

Results submitted2015-10-14

View on ClinicalTrials.gov More Reduction of Hypertrophic Skin Scarring trials